Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Cimzia gets positive opinion for PsA and approval for severe active axial spondyloarthritis

Oct. 29, 2013

Rigel provides update on two pipeline candidates

Oct. 29, 2013

Tissue Therapies files application to conduct pivotal VitroGro ECM trial

Oct. 28, 2013

Auxilium begins phase IIa study of Xiaflex for treatment of cellulite

Oct. 25, 2013

FDA accepts supplemental BLA filing for Xolair

Oct. 14, 2013

Pergamum reports final data from phase I/II LL-37 study in chronic leg ulcers

Oct. 11, 2013

Edimer begins phase II trial in XLHED-affected male newborns

Oct. 9, 2013

Continued clinical benefit of tildrakizumab for 1 year in chronic psoriasis

Oct. 9, 2013

Researchers present phase I results for the anti-IL-31 receptor antibody CIM-331

Oct. 7, 2013

Safety and efficacy of INCB-039110 confirmed in patients with psoriasis

Oct. 7, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.